Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Dyne Therapeutics, Inc.NASDAQ: DYN
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$1.7B, compared with -$1.18B a year earlier.
Context
- Retained earnings amounted to 170.6% of total assets at the end of Q2 FY2026, up 9.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -44.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (1.4B) USD
- Year-over-year change
- -47.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.4B) | -47.0% |
| FY2024 | 2024-12-31 | (949.93M) | -50.2% |
| FY2023 | 2023-12-31 | (632.51M) | -59.5% |
| FY2022 | 2022-12-31 | (396.57M) | -73.6% |
| FY2021 | 2021-12-31 | (228.47M) | — |
Retained Earnings vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's Jun 2026 retained earnings of -$1.7B is the 8th highest of the 11 companies compared; the peer median is -$781.12M.
- Its year-over-year change of -44.2% is the 7th highest of 11, against a peer median of -24.5%.
- Retained earnings amounts to 170.6% of total assets for DYN, versus a peer median of 133.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$312.81M | -113.2% | — | 93.2% | |
| Mar 2026 | -$338.82M | -51.1% | — | 103.8% | |
| Mar 2026 | -$378.88M | -25.6% | — | 242.4% | |
| Mar 2026 | -$464.44M | -55.6% | — | 222.7% | |
| Mar 2026 | -$547.72M | -44.9% | — | 123.6% | |
| Mar 2026 | -$1.01B | -23.3% | — | 239.9% | |
| Mar 2026 | -$1.35B | -15.7% | — | 231.7% | |
| Jun 2026 | -$1.7B | -44.2% | — | 170.6% | |
| Jun 2026 | -$2.88B | -1.3% | — | 88.7% | |
| Sep 2026 | -$2.95B | -22.8% | — | 101.2% | |
| Mar 2026 | -$4.55B | +2.4% | — | 143.0% | |
| Peer median (excluding DYN) | -$781.12M | -24.5% | — | 133.3% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 200.83M | 172.15M | 121.63M | 435.45M | 893.37M |
| Short-term Investments | 175.75M | 83.87M | 1.47M | 206.82M | 217.19M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 383K | 9.58M | 6.28M | 17.01M | 16.03M |
| Total Current Assets | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B |
| Property, Plant & Equipment (Net) | 40.96M | 38.41M | 33.39M | 30.01M | 44.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.31M | 2.32M | 2.32M | 1.94M | 15.6M |
| Total Non-current Assets | 43.27M | 40.73M | 35.71M | 31.96M | 60.37M |
| Total Assets | 425.66M | 306.33M | 165.08M | 691.23M | 1.19B |
| Account Payables | 4.03M | 5.26M | 22.94M | 6.56M | 8.08M |
| Short-term Debt | 0 | 0 | 0 | 4.85M | 5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 17.75M | 37.55M |
| Total Current Liabilities | 28.72M | 28.09M | 51.1M | 42.26M | 50.63M |
| Long-term Debt | 0 | 0 | 0 | 0 | 15.28M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 148.92M |
| Total Non-current Liabilities | 28.74M | 25.87M | 22.7M | 19.14M | 164.2M |
| Total Liabilities | 57.47M | 53.96M | 73.79M | 61.4M | 214.83M |
| Common Stock | 6K | 6K | 6K | 10K | 16K |
| Retained Earnings | (228.47M) | (396.57M) | (632.51M) | (949.93M) | (1.4B) |
| Accumulated OCI | (269K) | (571K) | 0 | 6K | 475K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 368.2M | 252.36M | 91.29M | 629.84M | 972.13M |
| Total Debt | 32.64M | 30.48M | 27.42M | 23.99M | 20.28M |
| Net Debt | (168.19M) | (141.66M) | (94.21M) | (411.46M) | (873.09M) |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.